Healthcare

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market – Industry Trends and Forecast to 2028

Healthcare | Published Report | May 2021 | MEA | 350 Pages | No of Tables: 47 | No of Figures: 22

Report Description

Middle East and Africa Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market, By Product (On-Premise Solutions, Cloud-Based Solutions, Web Based Solutions), Approach (Clinician Reported Outcome Assessment (ClinRO), Patient Reported Outcome Assessment (PRO), Observer Reported Outcome Assessment (ObsRO), Performance Outcome Assessment (PerfO)), End User (Commercial Service Providers, Hospitals and Transplant Centers, Research Laboratories, Academic Institutions), Platform (Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Medical Device Manufacturers, Hospitals and Clinical Laboratories, Consulting Service Companies, Research and Academia, Others), Country (U.A.E., Saudi Arabia, Egypt, South Africa, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Middle East and Africa Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market

The electronic clinical outcome assessment (eCOA) for content licensed market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the CAGR of 10.7% in the forecast period of 2021 to 2028 and expected to reach USD 55,922.13 thousands by 2028. The rise of electronic clinical outcome assessments (eCOAs) in the age of patient centricity which is accelerating the electronic clinical outcome assessment (eCOA) for content licensed market.

Electronic clinical outcome assessment (eCOA) is the method of capturing data electronically in clinical trials. It can substantially increase the quality of study data while meeting regulatory requirements. eCOA employs technologies such as handheld devices, tablets or the web to allow trial participants, physicians and caregivers to directly report information related to healthcare outcomes.

Growing demand for eCOA due to its capability to collect large amount of data while simultaneously ensuring high quality is accelerating the electronic clinical outcome assessment (eCOA) for content licensed market. High initial financial costs associated with the implementation and utilization of these systems might restrain the electronic clinical outcome assessment (eCOA) for content licensed market. Rising levels of innovations and technological advancements (AI, ML, precision trials, precision-guided intervention, IoMT) is creating opportunities for the electronic clinical outcome assessment (eCOA) for content licensed market. Lack of well-trained professionals for accurate data interpretation is a major challenge for the electronic clinical outcome assessment (eCOA) for content licensed market.

This electronic clinical outcome assessment (eCOA) for content licensed market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market Scope and Market Size

The electronic clinical outcome assessment (eCOA) for content licensed market is segmented on the basis of product, approach, end user and platform. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product, the electronic clinical outcome assessment (eCOA) for content licensed market is segmented into on-premise solutions, cloud-based solutions and web based solutions. In 2021, on-premise segment holds the largest market share in electronic clinical outcome assessment (eCOA) for content licensed market as on-premise is the perpetual license with a fixed set of studies available for clients.
  • On the basis of approach, the electronic clinical outcome assessment (eCOA) for content licensed market is segmented into clinician reported outcome assessment (ClinRO), patient reported outcome assessment (PRO), observer reported outcome assessment (ObsRO) and performance outcome assessment (PerfO). In 2021, clinician reported outcome assessment (ClinRO) segment holds the largest market share in electronic clinical outcome assessment (eCOA) for content licensed market as ClinRO measure involves a clinical judgment or interpretation of the observable signs, behaviours or other physical manifestations thought to be related to a disease or condition.
  • On the basis of end user, the electronic clinical outcome assessment (eCOA) for content licensed market is segmented into commercial service providers, hospitals and transplant centers and research laboratories and academic institutions. In 2021, research laboratories and academic institutions segment holds the largest market share in electronic clinical outcome assessment (eCOA) for content licensed market as research organization and academic institution used broadly within the clinical and drug development industries, primarily refers to an academic and/or non-profit institution that performs one or more functions in the conduct of clinical trials.
  • On the basis of platform, the electronic clinical outcome assessment (eCOA) for content licensed market is segmented into contract research organization, pharmaceutical and biopharmaceutical companies, medical device manufacturers, consulting service companies, hospitals and clinical laboratories, research and academia and others. In 2021, contract research organization segment holds the largest market share in electronic clinical outcome assessment (eCOA) for content licensed market as a contract research organization (CROs) is a service organization that provides support to the pharmaceutical and biotechnology industries in the form of outsourced pharmaceutical research services (for both drugs and medical devices).

Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market Country Level Analysis

Electronic clinical outcome assessment (eCOA) for content licensed market is analysed and market size information is provided by the country, product, approach, end user and platform.

The countries covered in electronic clinical outcome assessment (eCOA) for content licensed market report are South Africa, UAE, Saudi Arabia, Israel, Egypt and Rest of Middle East & Africa.

South Africa accounted largest market share due to increasing focus towards utilizing the potential of the clinical trial market in the region as pharma companies are attempting to reduce costs of offshore clinical trials.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Number of Clinical Trials

The electronic clinical outcome assessment (eCOA) for content licensed market also provides you with detailed market analysis for every country growth in industry with sales, components sales, impact of technological development in electronic clinical outcome assessment (eCOA) for content licensed and changes in regulatory scenarios with their support for the electronic clinical outcome assessment (eCOA) for content licensed market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Electronic Clinical Outcome Assessment (eCOA) for Content Licensed Market Share Analysis

The electronic clinical outcome assessment (eCOA) for content licensed market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to electronic clinical outcome assessment (eCOA) for content licensed market.

The major players covered in the report are Oracle, IBM Corporation, Dassault Systemes, Parexel International Corporation among others local and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product developments are also initiated by the companies worldwide which are also accelerating the growth of electronic clinical outcome assessment (eCOA) for content licensed market.

For instance,

  • In February 2021, ERT Clinical, a leading global data and technology company for clinical endpoint data collection has introduced a powerful new solution eCOA Multimedia for enabling the collection, processing and analysis of photos and audio as part of clinical trial eCOA assessments. With this new launch, the company has increased its product line.

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for electronic clinical outcome assessment (eCOA) for content licensed through expanded range of size.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 MIDDLE EAST AND AFRICA PRODUCT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 RISE OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) IN THE AGE OF PATIENT CENTRICITY

5.1.2 GROWING DEMAND FOR ECOA DUE TO ITS CAPABILITY TO COLLECT LARGE AMOUNTS OF DATA WHILE SIMULTANEOUSLY ENSURING HIGH QUALITY

5.1.3 EMERGING TECHNOLOGICAL TRENDS BY PROVIDING A GREATER UNDERSTANDING OF EDC AND ECOA/EPRO PENETRATION IN PHARMACEUTICAL MARKETS

5.1.4 GROWING ACCEPTANCE OF ECOA TO ENGAGE MORE CLOSELY WITH PATIENTS BY PHARMA INDUSTRY

5.1.5 RISING NEED TOWARDS ELECTRONIC DATA CAPTURING FOR EFFICIENCY OF CLINICAL TRIALS

5.1.6 COST-EFFICIENCY AND RELIABILITY PROVIDED BY THE ECOA

5.1.7 RISING NUMBER OF CLINICAL TRIALS REGULATED BY FDA AND APPROVED BY INSTITUTIONAL REVIEW BOARD (IRB) FOR PATIENT SAFETY IN MULTI-CENTER TRIALS

5.2 RESTRAINTS

5.2.1 HIGH INITIAL COSTS ASSOCIATED WITH THE IMPLEMENTATION AND UTILIZATION OF THE SYSTEMS

5.2.2 LACK OF AWARENESS ABOUT REGULATIONS RELATED TO THE DATA MANAGEMENT

5.3 OPPORTUNITIES

5.3.1 RISING LEVELS OF INNOVATIONS AND ADVANCED TECHNOLOGIES

5.3.2 INCREASING PARTNERSHIPS AND COLLABORATIONS FOR CLINICAL RESEARCHES

5.3.3 DIGITIZATION OF CLINICAL TRIALS AIMS AT PERFORMING THEIR END-TO-END DIGITAL TRANSFORMATION

5.3.4 INCREASING COLLABORATION BETWEEN INDUSTRY AND GOVERNMENT FOR CLINICAL TRIALS UNDER GOVERNMENT POLICIES

5.4 CHALLENGES

5.4.1 LACK OF WELL-TRAINED PROFESSIONALS FOR ACCURATE DATA INTERPRETATION

5.4.2 LACK OF PROPER IT INFRASTRUCTURE IN MANY DEVELOPING COUNTRIES

6 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT

6.1 OVERVIEW

6.2 ON-PREMISE SOLUTIONS

6.3 CLOUD BASED SOLUTIONS

6.4 WEB BASED SOLUTIONS

7 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH

7.1 OVERVIEW

7.2 CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO)

7.3 PATIENT REPORTED OUTCOME ASSESSMENT (PRO)

7.4 OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO)

7.5 PERFORMANCE OUTCOME ASSESSMENT (PERFO)

8 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER

8.1 OVERVIEW

8.2 RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS

8.3 HOSPITALS AND TRANSPLANT CENTERS

8.4 COMMERCIAL SERVICE PROVIDERS

9 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM

9.1 OVERVIEW

9.2 CONTRACT RESEARCH ORGANIZATIONS

9.3 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES

9.4 MEDICAL DEVICE MANUFACTURERS

9.5 HOSPITALS AND CLINICAL LABORATORIES

9.6 CONSULTING SERVICE COMPANIES

9.7 RESEARCH AND ACADEMIA

9.8 OTHERS

10 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET, BY REGION

10.1 MIDDLE EAST AND AFRICA

10.1.1 SOUTH AFRICA

10.1.2 UAE

10.1.3 ISRAEL

10.1.4 SAUDI ARABIA

10.1.5 EGYPT

10.1.6 REST OF MIDDLE EAST AND AFRICA

11 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY LANDSCAP

11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

12 SWOT ANALYSIS

13 COMPANY PROFILE

13.1 ORACLE

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 COMPANY SHARE ANALYSIS

13.1.4 PRODUCT PORTFOLIO

13.1.5 RECENT DEVELOPMENTS

13.2 PAREXEL INTERNATIONAL CORPORATION

13.2.1 COMPANY SNAPSHOT

13.2.2 COMPANY SHARE ANALYSIS

13.2.3 PRODUCT PORTFOLIO

13.2.4 RECENT DEVELOPMENTS

13.3 ERT CLINICAL

13.3.1 COMPANY SNAPSHOT

13.3.2 COMPANY SHARE ANALYSIS

13.3.3 PRODUCT PORTFOLIO

13.3.4 RECENT DEVELOPMENTS

13.4 DASSAULT SYSTÈMES

13.4.1 COMPANY SNAPSHOT

13.4.2 REVENUE ANALYSIS

13.4.3 COMPANY SHARE ANALYSIS

13.4.4 PRODUCT PORTFOLIO

13.4.5 RECENT DEVELOPMENTS

13.5 BIOCLINICA

13.5.1 COMPANY SNAPSHOT

13.5.2 COMPANY SHARE ANALYSIS

13.5.3 PRODUCT PORTFOLIO

13.5.4 RECENT DEVELOPMENTS

13.6 IBM CORPORATION

13.6.1 COMPANY SNAPSHOT

13.6.2 REVENUE ANALYSIS

13.6.3 PRODUCT PORTFOLIO

13.6.4 RECENT DEVELOPMENTS

13.7 CLINICAL INK

13.7.1 COMPANY SNAPSHOT

13.7.2 PRODUCT PORTFOLIO

13.7.3 RECENT DEVELOPMENTS

13.8 KAYENTIS

13.8.1 COMPANY SNAPSHOT

13.8.2 PRODUCT PORTFOLIO

13.8.3 RECENT DEVELOPMENTS

13.9 ANJU SOFTWARE, INC.

13.9.1 COMPANY SNAPSHOT

13.9.2 PRODUCT PORTFOLIO

13.9.3 RECENT DEVELOPMENTS

13.1 ARISMIDDLE EAST AND AFRICA

13.10.1 COMPANY SNAPSHOT

13.10.2 PRODUCT PORTFOLIO

13.10.3 RECENT DEVELOPMENTS

13.11 ECLINICAL SOLUTIONS LLC

13.11.1 COMPANY SNAPSHOT

13.11.2 PRODUCT PORTFOLIO

13.11.3 RECENT DEVELOPMENTS

13.12 SIGNANT HEALTH

13.12.1 COMPANY SNAPSHOT

13.12.2 SOLUTION PORTFOLIO

13.12.3 RECENT DEVELOPMENTS

13.13 WIRB-COPERNICUS GROUP

13.13.1 COMPANY SNAPSHOT

13.13.2 SERVICE PORTFOLIO

13.13.3 RECENT DEVELOPMENTS

13.14 YPRIME LLC

13.14.1 COMPANY SNAPSHOT

13.14.2 PRODUCT PORTFOLIO

13.14.3 RECENT DEVELOPMENTS

14 QUESTIONNAIRE

15 RELATED REPORTS

List of Table

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)

TABLE 2 MIDDLE EAST AND AFRICA ON-PREMISE SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 3 MIDDLE EAST AND AFRICA CLOUD BASED SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 4 MIDDLE EAST AND AFRICA WEB BASED SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 5 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)

TABLE 6 MIDDLE EAST AND AFRICA CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 7 MIDDLE EAST AND AFRICA PATIENT REPORTED OUTCOME ASSESSMENT (PRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 8 MIDDLE EAST AND AFRICA OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 9 MIDDLE EAST AND AFRICA PERFORMANCE OUTCOME ASSESSMENT (PERFO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 10 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 11 MIDDLE EAST AND AFRICA RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 12 MIDDLE EAST AND AFRICA HOSPITALS AND TRANSPLANT CENTERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 13 MIDDLE EAST AND AFRICA COMMERCIAL SERVICE PROVIDERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 14 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)

TABLE 15 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 16 MIDDLE EAST AND AFRICA PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 17 MIDDLE EAST AND AFRICA MEDICAL DEVICE MANUFACTURERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 18 MIDDLE EAST AND AFRICA HOSPITALS AND CLINICAL LABORATORIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 19 MIDDLE EAST AND AFRICA CONSULTING SERVICE COMPANIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 20 MIDDLE EAST AND AFRICA RESEARCH AND ACADEMIA IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 22 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)

TABLE 23 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)

TABLE 24 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)

TABLE 25 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 26 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)

TABLE 27 SOUTH AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)

TABLE 28 SOUTH AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)

TABLE 29 SOUTH AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 30 SOUTH AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)

TABLE 31 UAE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)

TABLE 32 UAE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)

TABLE 33 UAE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 34 UAE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)

TABLE 35 ISRAEL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)

TABLE 36 ISRAEL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)

TABLE 37 ISRAEL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 38 ISRAEL ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)

TABLE 39 SAUDI ARABIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)

TABLE 40 SAUDI ARABIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)

TABLE 41 SAUDI ARABIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 42 SAUDI ARABIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)

TABLE 43 EGYPT ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)

TABLE 44 EGYPT ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)

TABLE 45 EGYPT ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)

TABLE 46 EGYPT ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)

TABLE 47 REST OF MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)

List of Figure

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION

FIGURE 10 GROWING ACCEPTANCE OF ECOA TO ENGAGE MORE CLOSELY WITH PATIENTS BY PHARMA INDUSTRY IS EXPECTED TO DRIVE MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 ON-PREMISE SOLUTIONS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN 2021 & 2028

FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET

FIGURE 13 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT, 2020

FIGURE 14 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY APPROACH, 2020

FIGURE 15 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY END USER, 2020

FIGURE 16 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PLATFORM, 2020

FIGURE 17 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020)

FIGURE 18 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020)

FIGURE 19 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028)

FIGURE 20 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028)

FIGURE 21 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028)

FIGURE 22 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY SHARE 2020(%)

 

View Infographics

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION

FIGURE 10 GROWING ACCEPTANCE OF ECOA TO ENGAGE MORE CLOSELY WITH PATIENTS BY PHARMA INDUSTRY IS EXPECTED TO DRIVE MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 ON-PREMISE SOLUTIONS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN 2021 & 2028

FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET

FIGURE 13 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT, 2020

FIGURE 14 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY APPROACH, 2020

FIGURE 15 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY END USER, 2020

FIGURE 16 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PLATFORM, 2020

FIGURE 17 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020)

FIGURE 18 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020)

FIGURE 19 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028)

FIGURE 20 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028)

FIGURE 21 MIDDLE EAST AND AFRICA ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028)

FIGURE 22 MIDDLE EAST AND AFRICA ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY SHARE 2020(%)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19